Chromista

Chromis Therapeutics is a biotechnology company focused on developing novel small molecule therapies for the treatment of chronic Hepatitis B virus (HBV) infection. The company's primary approach involves the development of core protein allosteric modulators (CpAMs) designed to disrupt the viral lifecycle and achieve a functional cure. By targeting the HBV core protein, Chromis aims to inhibit both the assembly of new viral particles and the replenishment of the cccDNA reservoir. The company is led by a team with significant experience in antiviral drug discovery and development, particularly in the field of liver diseases.